Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Xerox wants to give HP’s board its walking papers We’re all guilty of overusing the David v Goliath trope but in the case of Xerox and HP, it really does apply....
...Now its market capitalisation languishes at $52bn — less than half what Pfizer was willing to pay....
...“Critical to ultimate value creation in this transaction is a return to growth in Xtandi,” says Seamus Fernandez, an analyst at Leerink....
...Seamus Fernandez, analyst at Leerink, estimated that half of the deal’s benefits would come from tax savings and said the “biggest risk” it faced was a change in the rules on intra-company loans....
...It was these prospects that gave AstraZeneca the confidence to resist a £69.4bn bid from Pfizer in 2014....
...“This removes Merck’s biggest overhang,” said Seamus Fernandez, an analyst at Leerink....
...Seamus Fernandez, an analyst at Leerink, says a recent deal with Celgene involving a $450m upfront payment in return for a half share of future revenues from the use of MEDI4736 against blood cancers suggested...
...“AstraZeneca has firmly established that it is no longer a dark horse but a major potential participant in immuno-oncology,” said Mr Fernandez....
...Seamus Fernandez, analyst at Leerink, said: “We view Pfizer-Actavis as financially and operationally sound with a potentially willing target....
...Mr Fernandez at Leerink said the acquisition would create a “more compelling entity” and give Pfizer “greater optionality for a successful separation” of its three units....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“The whole immuno-oncology area is exploding,” says John LaMattina, former head of research and development for Pfizer....
...run high as East Asia Summit ends * PICC said to seek up to $3.6bn in Hong Kong initial offer * Japanese investment in China falls sharply * Egypt and IMF agree $4.8bn loan * Mexico rejects Nestlé-Pfizer...
...deal * Argentina’s Fernandez faces her first general strike * Pakistan stocks perform despite violence * Markets: mainly up Glencore-Xstrata to win EU clearance The Glencore-Xstrata merger is set to...
...China milk group eyes Pfizer baby food unit Mengniu Dairy, one of China’s largest milk producers, is considering a bid for Pfizer’s infant nutrition business as potential buyers prepare for the start of...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Fernández wins re-election in Argentina Cristina Fernández, Argentina’s populist centre-left president, has won a historic re-election victory by the widest margin in four decades and used an emotion-charged...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
International Edition